Benjamin C. Lin
34 works · 974 citations · h-index 8
Top works
- Liver-specific Activities of FGF19 Require Klotho beta
- Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
- Stimulating the GPR30 Estrogen Receptor with a Novel Tamoxifen Analogue Activates SF-1 and Promotes Endometrial Cell Proliferation
- A Conformational Switch in Nuclear Hormone Receptors Is Involved in Coupling Hormone Binding to Corepressor Release
- Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4
- FGF19 and Cancer
- Plasticity of Tetramer Formation by Retinoid X Receptors
- MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Deciphering Intracellular Signaling Regulating Directed Cell Migration
- Supplemental Figure 5 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figure 2 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figure 4 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figure 4 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figure 8 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Data from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Table 1 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Data from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figures 6 and 7 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figure 5 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer
- Supplemental Figures 6 and 7 from MMP-1 and Pro-MMP-10 as Potential Urinary Pharmacodynamic Biomarkers of FGFR3-Targeted Therapy in Patients with Bladder Cancer